Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Urate anion transporter 1 (URAT1), encoded by the SLC22A12 gene, is a membrane protein predominantly expressed in the proximal tubule of the kidney. It is the principal transporter responsible for mediating the re-absorption of uric acid from the renal filtrate back into circulation. URAT1, along with OAT4 and GLUT9, is central to maintaining serum urate levels. Dysfunction or inhibition of URAT1 can lead to changes in urate balance and contribute to conditions such as gout or kidney disease. Therapeutic inhibition of URAT1 is a key strategy in treating gout and hyperuricemia.
Competitive inhibition of renal urate re-absorption via direct binding to transporter (especially URAT1) Increased renal uric acid excretion (uricosuric action)
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Urate anion transporter 1 (URAT1).